Biotech IPOs Lead August as SpaceX Unlock and Reg NMS Overhaul Reshape Market Structure

The US IPO market entered August with surprising momentum. Six companies priced offerings in the first full week of the month — four of them biotechs — while the market’s largest recent listing, SpaceX, navigated its first lock-up release and the SEC’s proposal to rescind the trade-through rule that has undergirded equity market structure for two decades entered its comment period. The convergence of these threads — a biotech-led issuance wave, a mega-IPO’s float expansion, and a regulatory plumbing overhaul — makes this an unusually information-rich moment for anyone tracking how capital formation and market mechanics interact.

Biotech Carries the August Pipeline

The week of August 3 saw six IPOs and five SPACs price, bringing the year’s US IPO count to 225 through August 8 — a 6.6% increase over the 211 listings recorded by the same date in 2025^[1].

The standout was Braveheart Bio (BRVE), a cardiovascular biotech whose lead candidate, an oral cardiac myosin inhibitor licensed from China’s Hengrui Pharmaceuticals, is Phase 3-ready. The deal was upsized and priced above the range, raising $383 million at a $1.6 billion market cap. The stock finished the week up 67%^[2].

Three more biotechs followed:

Latigo Biotherapeutics (LTGO), developing a non-opioid Nav1.8 inhibitor for acute pain, priced at the top of its range and raised $346 million at a $1.3 billion market cap^[2]. Attovia Therapeutics (ATTO), whose ATTOBODY platform targets immune-mediated diseases, raised $289 million and gained 19% on the week^[2]. BlossomHill Therapeutics (BLSM), focused on EGFR-mutant non-small cell lung cancer, raised $150 million and finished flat^[2].

The pattern is telling. Biotech issuance has been the steadiest sector for new listings throughout 2026, and investors have shown a clear preference for companies with Phase 2-ready or Phase 3-ready assets — where clinical de-risking has already occurred. Braveheart’s 67% first-week gain and Apnimed’s 69% return from late July both reflect that appetite. Earlier-stage programs command less enthusiasm: BlossomHill, which is still in Phase 1/2, drew no premium.

Rounding out the week, California’s River City Bank (RCBC) downsized and priced below range to raise $122 million, finishing up 4%^[2]. Latin American ticketing platform Ticketplus (TP) priced at the bottom of its range, raised $15 million, and dropped 13%^[2].

SpaceX: The $101 Billion Unlock

SpaceX (SPCX) went public on June 12 at $135 per share in the largest US IPO in history. Fewer than 5% of its shares were sold in the offering^[3]. On August 6, the first of several lock-up restrictions expired, freeing 911.5 million shares for potential sale — a pool worth roughly $101 billion at the time^[3].

The stock’s journey since its debut has been rough. Shares have lost more than a quarter of their value since the IPO, trading at $133.11 as of August 10, well below the $135 offer price^[1]. The slide accelerated after SpaceX’s first earnings report on August 4, which beat revenue expectations but revealed higher-than-anticipated AI infrastructure spending, sending the stock down 7% in after-hours trading^[4]. Short sellers had already accumulated roughly $9 billion in paper profits^[5].

Yet on the day of the unlock itself, SpaceX shares rose 1.4% to $109.86 on heavy volume — over $23 billion worth of shares exchanged by midday, on track for the busiest session since the stock’s addition to the Nasdaq 100 on July 7^[3]. The market absorbed the new supply more gracefully than many expected. This is consistent with lock-up expiry literature: the event is anticipated and largely priced in ahead of time, and the absence of a forced-selling cascade can produce a relief rally.

But the unlock story is not over. By December 8, a series of staged releases will increase SpaceX’s potentially tradeable float to 40% of the company^[3]. The remaining 60%, including Elon Musk’s stake, stays locked until mid-2027. Each tranche is a separate liquidity test.

The trajectory here matters. A stock that has already declined 25% from its IPO price, with short sellers firmly in profit and AI capex concerns weighing on sentiment, faces a structural float increase of roughly 8x over six months. Even if each individual unlock passes without a sell-off, the cumulative supply overhang is real. The base rate says lock-up expiries typically produce modest, temporary pressure — but the base rate does not cover a mega-IPO with this little initial float and this much pre-existing weakness.

Consumer IPOs Test Deeper Water

The prior week offered a different data point: consumer issuance. Jersey Mike’s Subs (JMKE) priced at $23 — the midpoint of its $21–$25 range — raising $1 billion in the largest restaurant IPO since 2011, at an initial valuation of roughly $7.3 billion^[6][7]. The stock opened at $21, broke issue price on day one, and recouped its losses to close roughly flat. As of August 10, it trades at $22.91, down 0.4% from offer^[1].

Direct-to-consumer womenswear brand Reformation (REF) priced at the low end of its range and posted an 8% first-day gain^[7]. It currently trades at $15.76, up 5.1%^[1].

The takeaway from the consumer deals is mixed. Issuance got done — which is the prerequisite data point — but investors demanded concessions. Jersey Mike’s had to accept the midpoint rather than the high end, and the stock still broke issue price before recovering. Reformation priced at the low end. For a pipeline that has been dominated by biotech and technology, the message is that consumer deals can clear, but at a discount.

The Reg NMS Overhaul: Rewriting Market Plumbing

While the IPO market captures headlines, a more consequential shift is unfolding in market structure regulation. On June 11, 2026, the SEC proposed rescinding Rule 611 of Regulation NMS — the trade-through prohibition — and Rule 610(e), which restricts locked and crossed quotations^[8].

Rule 611, adopted in 2005, requires trading centers to execute orders at prices equal to or better than the best displayed quotation across all venues (the NBBO). It has been the backbone of US equity market structure for two decades. Chairman Paul Atkins framed the proposal as correcting unintended consequences: “After two decades of Rule 611, it is high time that the Commission review its unintended consequences that have hindered — rather than enhanced — the long-term growth of our markets”^[8].

The SEC’s proposed amendments would rescind Rule 611 entirely, rescind Rule 610(e)’s restrictions on locking and crossing quotations, and make conforming changes to related provisions^[8]. The public comment period runs 60 days from Federal Register publication.

FINRA moved quickly to follow. On July 24, 2026, it published Regulatory Notice 26-15, seeking industry input on potential changes to its best execution rule, Rule 5310^[9]. The notice asks whether the NBBO will remain an important benchmark for firms after Rule 611’s rescission, whether FINRA should adopt safe harbors for best execution compliance, and whether order-by-order review should be required for internalized orders^[9].

FINRA also raised nine categories of questions, including the application of best execution to listed options, the treatment of institutional versus retail orders, extended-hours trading guidance, and the implications of emerging technologies such as generative AI and tokenization for execution quality^[9]. Comments are due September 25, 2026.

This is not a minor adjustment. If Rule 611 is rescinded, brokers would no longer be obligated to route orders to the venue displaying the best price. The SEC argues the NBBO backstop is no longer needed given market evolution since 2005 — but the counterargument is that removing the trade-through prohibition could fragment execution quality and increase the complexity of best-execution compliance, particularly for retail orders. The FINRA notice’s request for potential safe harbors suggests regulators are aware that firms will need clearer guardrails if the existing framework is dismantled.

The broader context reinforces why this matters now. Citadel Securities’ Scott Rubner described the defining story of 2026 as “the structural transformation of equity markets” — driven by concentration, passive investing, and retail participation — rather than any single macro event^[10]. The Renaissance IPO Index is up 18.8% year-to-date versus the S&P 500’s 13.4%, and the International IPO Index is up 40.0%^[2]. New issuance is accelerating into a market whose plumbing is being rewritten.

What to Watch Next

• Londian Wason (FOIL): The sole sizable US IPO scheduled for the week of August 10. The China-based copper foil producer aims to raise $75 million at a $1.6 billion market cap, with investors led by China’s Harvest Fund Management indicating on 115% of the offering at the midpoint^[11].

• Summer window closing: Renaissance Capital notes that in a typical year, companies have roughly one more week to launch offerings before the IPO market breaks for summer^[11]. Whether issuers push through or pause will signal conviction about autumn demand.

• SpaceX staged unlocks: Subsequent lock-up releases through December 8 will progressively increase tradeable float to 40% of the company^[3]. Each tranche is a separate test of whether the market can absorb supply without disruption.

• Six IPO lock-up releases: Renaissance counts six lock-up expiries in the coming week, alongside Street research initiations on Csquare (CSQR) and Standard Nuclear (STDN)^[11].

• FINRA comment deadline (September 25): Industry responses to Regulatory Notice 26-15 will shape the next generation of best-execution guidance^[9]. The positions firms stake out on safe harbors, institutional order handling, and AI-driven execution will influence how the post-Reg NMS market operates.

• Renaissance IPO Index performance: At 18.8% YTD versus the S&P 500’s 13.4%, the IPO index’s relative strength is a gauge of whether newly public companies are sustaining post-debut momentum — or whether the gap narrows as larger recent listings like SpaceX weigh on the index^[2].